Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SeMaglutide and Albuminuria Reduction Trial in obese individuals without diabetes
2021-001247-27Phase 3Completed
- Sponsor
- University Medical Center Groningen
- Start
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) and obesity comparing Semaglutide arm with Placebo arm (2 arms). Primary endpoint: Change in urinary albumin:creatinine ratio from baseline to week 24. Started Jun 2021; status: completed.
02
Drugs
03
Conditions
chronic kidney disease (CKD)obesity
Beyond the preview
Go deeper on 2021-001247-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001247-27.